Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

Neumora’s failed trials and layoffs signal deep trouble, not a turnaround opportunity.

Risk flags

• ●Lead asset failure: The failure of both Phase 3 KOASTAL-2 and KOASTAL-3 trials eliminates the company’s primary value driver. This is a catastrophic event for a biotech at this stage, as it leaves the pipeline and future revenue prospects in question.
• ●Massive workforce reduction: The immediate ~35% cut in staff signals severe cost pressures and likely operational disruption. Such a large reduction often leads to loss of institutional knowledge, morale issues, and impaired ability to execute on any remaining programs.
• ●Stock collapse: A nearly 50% drop in share price reflects a market consensus that the company’s prospects have fundamentally deteriorated. This also increases the risk of delisting, hostile takeover, or further capital constraints.
• ●Opaque financial disclosure: The announcement omits key financial metrics such as cash position, burn rate, and runway. This lack of transparency makes it impossible for investors to assess the company’s ability to survive or pivot.
• ●Litigation risk: The initiation of a securities investigation by Levi & Korsinsky, LLP into potentially false or misleading statements about financial condition and clinical program status introduces the risk of costly legal proceedings, settlements, or regulatory penalties.
• ●Forward-looking claims are now moot: The only forward-looking statement—plans for next steps after a successful readout—is no longer relevant, as the readout was negative. This leaves investors with no credible path to future value.
• ●No evidence of institutional support: There is no mention of new investment, partnerships, or support from major industry players. The absence of such backing increases the risk that the company will be unable to raise additional capital or attract strategic interest.
• ●Pattern of evasive communication: Management’s failure to mention the workforce reduction during the earnings call, despite its materiality, suggests a tendency to downplay negative developments. This pattern increases the risk of further unpleasant surprises for investors.

Bottom line

For investors, this announcement is a clear signal to reassess any bullish thesis on Neumora Therapeutics. The failure of both pivotal Phase 3 trials for navacaprant removes the company’s main value proposition and leaves its future highly uncertain. The immediate ~35% workforce reduction is a drastic measure that underscores the severity of the setback and likely impairs the company’s ability to execute on any remaining pipeline assets. The nearly 50% collapse in share price is a rational market response to these events, and there is no evidence of a credible recovery plan or new strategic direction. The initiation of a securities litigation investigation by a top-ranked firm further increases the risk profile, as it could lead to costly legal outcomes and further erode shareholder value. Management’s communications are evasive and fail to provide the transparency or forward guidance that investors need to make informed decisions. To change this assessment, the company would need to disclose detailed financials (cash runway, burn rate), a concrete plan for pipeline reprioritization, and clear milestones for any new programs. In the next reporting period, investors should watch for updates on cash position, any new clinical or business development initiatives, and the status of the legal investigation. At present, the information provided is a strong negative signal—this is not a buying opportunity, but rather a situation to monitor for further deterioration or, at best, signs of stabilization. The single most important takeaway is that Neumora’s investment case has fundamentally changed for the worse, and absent new, credible disclosures, the risk of further downside remains high.

Announcement summary

(NASDAQ: NMRA) Neumora Therapeutics reported that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder, resulting in the stock falling nearly 50%. The company announced an immediate ~35% workforce reduction following the trial failures. During its Q4 2025 earnings call on March 30, 2026, COO Aurora discussed plans on next steps only following a successful readout and made no mention of the workforce reduction. On January 5, 2026, Neumora's President Pinto discussed the company's decision to increase the size of the patient population by 25% in the KOASTAL-2 and KOASTAL-3 studies. Levi & Korsinsky, LLP, a Top 50 securities litigation firm (ISS, seven consecutive years), is investigating whether Neumora Therapeutics made materially false or misleading statements regarding its financial condition, asset values, and the status of its navacaprant clinical program. Over 70 professionals at Levi & Korsinsky, LLP have recovered hundreds of millions. The investigation covers investors who purchased NMRA stock or securities and suffered financial losses.

Disagree with this article?